On February 5, 2018 H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of next generation cancer medicines using its data science and precision chemistry product engine, reported that company management will present an overview of the company at the 2018 BIO CEO & Investor Conference on Monday, February 12, 2018, at 9:45 a.m. EST at the New York Marriott Marquis in New York (Press release, H3 Biomedicine, FEB 5, 2018, View Source [SID1234523723]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 5, 2018 Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) reportd that it will be announcing its final results for the year ended December 31, 2017 on Monday, March 12, 2018 at 7:00 am Greenwich Mean Time (GMT) (Press release, Hutchison China MediTech, FEB 5, 2018, View Source [SID1234523724]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An analyst presentation will be held at 9:00 am GMT (5:00 pm Hong Kong Time) on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY, UK, which will be webcast via the company website at www.chi-med.com/investors/event-information/. The presentation will be available to download before the analyst presentation begins.

For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Daylight Time (1:00 pm GMT).

Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event.

On February 5, 2018 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, is pleased to announce the signing of a Letter of Intent with Urology Clinics of North Texas (UCNT) for the purpose of initiating a Phase 2 Clinical Trial of ProscaVax in advanced prostate cancer patients (Press release, Oncbiomune, FEB 5, 2018, View Source [SID1234524043]). ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. James S. Cochran, M.D., D.A.B.U., F.A.C.S., UCNT Medical Director, has agreed to serve as the trial’s Principal Investigator. Dr. Cochran has over 30 years of clinical practice experience and has participated in and provided oversight in more than 300 clinical trials.

"Ever since I learned of ProscaVax, I have been highly interested in its potential benefit to the thousands of prostate cancer patients with late-stage disease that face a bleak prognosis with negligible therapeutic options," commented Dr. Cochran. "Now that I have reviewed the data from the Phase 1 Clinical Trial, I believe this immunotherapy has the potential to be a game-changer in urology. I am extremely eager to move this trial forward expeditiously to address an area of great unmet medical need."

UCNT is an award-winning organization servicing the Dallas Metroplex area, the fifth most populous area in North America with approximately 6.5 million people in 13 counties. The organization is comprised of 16 private urology practices and over 40 providers with approximately half a million patients in their database.

"We could not be more pleased that Dr. Cochran and the esteemed prostate cancer experts at UCNT have such a strong desire to be a part of the clinical development of ProscaVax; it truly speaks highly of the vaccine’s potential," said Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "Given their decades of experience and robust patient population, we expect the mid-stage study to go very smoothly, with no enrollment competition whatsoever, which should allow the trial to progress quickly. The study will be a great complement to our planned study at a major Northeast university in early-stage prostate cancer patients, for which we anticipate reporting news on commencing that trial as well in the near term."

OncBioMune will release more details on the trial in collaboration with UCNT as they become available in the coming weeks.

Sign up for OncBioMune email alerts at: View Source

On February 5, 2018 Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) reported that it’s President, Chief Executive Officer and co-founder, Steven J. Mento, Ph.D., and Conatus Executive Vice President, Chief Operating Officer and Chief Financial Officer, Keith W. Marshall, Ph.D., M.B.A., will focus on the company’s expected announcements of clinical trial results and strategic development activities, in a presentation and in scheduled meetings with members of the investment community in New York next week (Press release, Conatus Pharmaceuticals, FEB 5, 2018, View Source [SID1234523755]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This is an exciting time for Conatus. We are now rapidly approaching four scheduled Phase 2b clinical trial readouts from our lead development program in 2018 and 2019, along with multiple parallel pathways to expanding our development pipeline," said Dr. Mento, "and we believe Conatus is advancing well toward the next chapter in the company’s evolution."

"With the funds provided by our collaboration with Novartis, including anticipated reimbursements for 50% of the costs for the four ongoing clinical trials," said Dr. Marshall, "the remaining emricasan development is fully funded. In addition, we believe these financial resources, without including any potential milestone payments under the Novartis collaboration, are sufficient to maintain operations through completion of all four Phase 2b clinical trials by the end of 2019, as well as to fund initial pipeline expansion activities. We will provide additional financial guidance for 2018 with our year-end financial results in early March."

At the Biotechnology Industry Organization (BIO) CEO & Investor Conference BIO CEO & Investor Conference in New York on Monday, February 12, Dr. Mento and Dr. Marshall will meet with investment professionals and will provide an overview and update presentation beginning at 10:30 a.m. ET. An audio webcast and copy of the BIO CEO & Investor Conference presentation will be available in the Investors section of the company’s website at www.conatuspharma.com.

At the SunTrust Robinson Humphrey Orphan Drug Day in New York on Tuesday, February 13, Dr. Mento and Dr. Marshall will conduct a series of meetings with invited institutional investors.

On February 5, 2018 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported that Adelene Perkins, Infinity Pharmaceutical’s chief executive officer, will present at the BIO CEO & Investor Conference on Monday, February 12, 2018, at 11:00 a.m. EST at The New York Marriott in New York, NY (Press release, Infinity Pharmaceuticals, FEB 5, 2018, View Source [SID1234523725]). A live webcast of the presentation will be available on the Investors/Media section of Infinity’s website at www.infi.com, and will be available for 30 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!